Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/123475
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hortelão, Ana C. | - |
dc.contributor.author | Patiño, Tania | - |
dc.contributor.author | Pérez Jiménez, Ariadna | - |
dc.contributor.author | Blanco, Ángel | - |
dc.contributor.author | Sánchez Ordóñez, Samuel | - |
dc.date.accessioned | 2018-07-11T13:07:48Z | - |
dc.date.available | 2018-11-27T06:10:17Z | - |
dc.date.issued | 2017-11-27 | - |
dc.identifier.uri | http://hdl.handle.net/2445/123475 | - |
dc.description.abstract | The use of enzyme catalysis to power micro- and nanomotors exploiting biocompatible fuels has opened new ventures for biomedical applications such as the active transport and delivery of specific drugs to the site of interest. Here, urease-powered nanomotors (nanobots) for doxorubicin (Dox) anticancer drug loading, release, and efficient delivery to cells are presented. These mesoporous silica-based core-shell nanobots are able to self-propel in ionic media, as confirmed by optical tracking and dynamic light scattering analysis. A four-fold increase in drug release is achieved by nanobots after 6 h compared to their passive counterparts. Furthermore, the use of Dox-loaded nanobots presents an enhanced anticancer efficiency toward HeLa cells, which arises from a synergistic effect of the enhanced drug release and the ammonia produced at high concentrations of urea substrate. A higher content of Dox inside HeLa cells is detected after 1, 4, 6, and 24 h incubation with active nanobots compared to passive Dox-loaded nanoparticles. The improvement in drug delivery efficiency achieved by enzyme-powered nanobots may hold potential toward their use in future biomedical applications such as the substrate-triggered release of drugs in target locations. | ca |
dc.format.extent | 24 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | Wiley | - |
dc.relation.isformatof | Versió postprint del document publicat a: http://dx.doi.org/10.1002/adfm.201705086 | - |
dc.relation.ispartof | Advanced Functional Materials, 2018, vol. 28, p. 1705086 | - |
dc.relation.uri | http://dx.doi.org/10.1002/adfm.201705086 | - |
dc.rights | (c) Wiley, 2017 | - |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Nanotecnologia | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.other | Nanotechnology | - |
dc.subject.other | Antineoplastic agents | - |
dc.title | Enzyme-powered nanobots enhance anticancer drug delivery | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/311529/EU//LT-NRBS | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
L21_2018_Advanced Functional Materials_28_1705086_OA.pdf | 2.11 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.